HRP20221240T1 - Deuterirani analozi etifoksina, njihovi derivati i njihove uporabe - Google Patents
Deuterirani analozi etifoksina, njihovi derivati i njihove uporabe Download PDFInfo
- Publication number
- HRP20221240T1 HRP20221240T1 HRP20221240TT HRP20221240T HRP20221240T1 HR P20221240 T1 HRP20221240 T1 HR P20221240T1 HR P20221240T T HRP20221240T T HR P20221240TT HR P20221240 T HRP20221240 T HR P20221240T HR P20221240 T1 HRP20221240 T1 HR P20221240T1
- Authority
- HR
- Croatia
- Prior art keywords
- disorder
- disease
- neuropathy
- compound
- dementia
- Prior art date
Links
- IBYCYJFUEJQSMK-UHFFFAOYSA-N etifoxine Chemical compound O1C(NCC)=NC2=CC=C(Cl)C=C2C1(C)C1=CC=CC=C1 IBYCYJFUEJQSMK-UHFFFAOYSA-N 0.000 title 1
- 229960003817 etifoxine Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 9
- 206010012289 Dementia Diseases 0.000 claims 6
- 208000019901 Anxiety disease Diseases 0.000 claims 5
- 208000033808 peripheral neuropathy Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 201000001119 neuropathy Diseases 0.000 claims 4
- 230000007823 neuropathy Effects 0.000 claims 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 3
- 229910052805 deuterium Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- IBYCYJFUEJQSMK-WNWXXORZSA-N 6-chloro-4-methyl-N-(1,1,2,2,2-pentadeuterioethyl)-4-phenyl-1H-3,1-benzoxazin-2-imine Chemical compound ClC=1C=CC2=C(C(OC(=N2)NC(C([2H])([2H])[2H])([2H])[2H])(C2=CC=CC=C2)C)C=1 IBYCYJFUEJQSMK-WNWXXORZSA-N 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000017194 Affective disease Diseases 0.000 claims 1
- 206010001488 Aggression Diseases 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010021118 Hypotonia Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010027944 Mood disorder due to a general medical condition Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010052794 Panic disorder with agoraphobia Diseases 0.000 claims 1
- 206010033668 Panic disorder without agoraphobia Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims 1
- 206010048734 Phakomatosis Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 206010057430 Retinal injury Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000003028 Stuttering Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000011962 Substance-induced mood disease Diseases 0.000 claims 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000022257 bipolar II disease Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000026725 cyclothymic disease Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000036640 muscle relaxation Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562135979P | 2015-03-20 | 2015-03-20 | |
| EP16769437.1A EP3347006B1 (en) | 2015-03-20 | 2016-03-18 | Deuterated analogs of etifoxine, their derivatives and uses therof |
| PCT/US2016/023231 WO2016154039A1 (en) | 2015-03-20 | 2016-03-18 | Deuterated analogs of etifoxine, their derivatives and uses therof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221240T1 true HRP20221240T1 (hr) | 2022-12-09 |
Family
ID=56977741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221240TT HRP20221240T1 (hr) | 2015-03-20 | 2016-03-18 | Deuterirani analozi etifoksina, njihovi derivati i njihove uporabe |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US10080755B2 (enExample) |
| EP (1) | EP3347006B1 (enExample) |
| JP (3) | JP6762507B2 (enExample) |
| KR (1) | KR102290766B1 (enExample) |
| CN (1) | CN107530323B (enExample) |
| AU (2) | AU2016235495B2 (enExample) |
| BR (1) | BR112017020081B1 (enExample) |
| CA (1) | CA2979853C (enExample) |
| DK (1) | DK3347006T3 (enExample) |
| ES (1) | ES2928396T3 (enExample) |
| HR (1) | HRP20221240T1 (enExample) |
| HU (1) | HUE060240T2 (enExample) |
| IL (2) | IL270627B2 (enExample) |
| LT (1) | LT3347006T (enExample) |
| MX (1) | MX383647B (enExample) |
| PL (1) | PL3347006T3 (enExample) |
| PT (1) | PT3347006T (enExample) |
| RS (1) | RS63654B1 (enExample) |
| SI (1) | SI3347006T1 (enExample) |
| SM (1) | SMT202200407T1 (enExample) |
| WO (1) | WO2016154039A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3347006T3 (pl) * | 2015-03-20 | 2022-11-14 | Gaba Therapeutics Inc. | Deuterowane analogi etifoksyny, ich pochodne i ich zastosowania |
| US10420773B2 (en) * | 2017-09-26 | 2019-09-24 | Ovid Therapeutics Inc. | Methods of treating developmental disorders and/or seizure disorders with etifoxine |
| CA3093430A1 (en) * | 2018-03-23 | 2019-09-26 | Concert Pharmaceuticals, Inc. | Deuterated analogs of d-.beta.-hydroxybutyric acid and uses thereof |
| WO2019222581A1 (en) * | 2018-05-18 | 2019-11-21 | Ovid Therapeutics Inc. | Methods of treating attention deficit hyperactivity disorder |
| CN112125862A (zh) * | 2019-06-25 | 2020-12-25 | 上海安谱实验科技股份有限公司 | 一种稳定同位素标记的阿特拉津-d5及其合成方法 |
| US11534434B2 (en) | 2019-11-15 | 2022-12-27 | Karuna Therapeutics, Inc. | Xanomeline derivatives and methods for treating neurological disorders |
| WO2023040851A1 (zh) * | 2021-09-14 | 2023-03-23 | 南京迈诺威医药科技有限公司 | 一种水溶性别孕烷醇酮衍生物及其制备方法和用途 |
| WO2023218251A1 (en) * | 2022-05-10 | 2023-11-16 | Clearsynth Labs Limied | Novel deuterium-enriched nefazodone analogues and method for preparing thereof |
| WO2024091943A2 (en) * | 2022-10-24 | 2024-05-02 | Gaba Therapeutics Inc. | Deuterated analogs of etifoxine and methods of administration without autoinduction of metabolism |
| WO2025085958A1 (en) * | 2023-10-23 | 2025-05-01 | Glomesh Intl Pty Ltd | A module for mounting items |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1670772C3 (de) | 1966-11-24 | 1978-04-20 | Hoechst Ag, 6000 Frankfurt | 4H-3,1-Benzoxazin-Derivate, deren Salze und pharmazeutische Präparate |
| FR2888748B1 (fr) * | 2005-07-19 | 2007-10-12 | Biocodex | Composes neuroprotecteurs et compositions pharmaceutiques les comprenant |
| CA2646007A1 (en) * | 2006-03-20 | 2007-09-27 | Xytis Inc. | Enantiomerically pure s-etifoxine, pharmaceutical compositions thereof and methods of their use |
| WO2007109288A2 (en) * | 2006-03-20 | 2007-09-27 | Xytis Inc. | Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use |
| JP2011001308A (ja) * | 2009-06-19 | 2011-01-06 | Research Foundation Itsuu Laboratory | 重水素化カルボスチリル化合物 |
| JP2013535437A (ja) * | 2010-07-09 | 2013-09-12 | テバ ファーマシューティカル インダストリーズ リミティド | 重水素化されたｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４−ヒドロキシ−５−クロロ−１−メチル−２−オキソキノリン−３−カルボキサミド、その塩および使用 |
| US20140121407A1 (en) | 2011-07-05 | 2014-05-01 | Research Foundation Itsuu Laboratory | Deuterated phenylpropionic acid derivative |
| FR3016881B1 (fr) | 2014-01-29 | 2016-03-04 | Biocodex | Traitement des degenerescences et des lesions photo-induites de la retine |
| PL3347006T3 (pl) * | 2015-03-20 | 2022-11-14 | Gaba Therapeutics Inc. | Deuterowane analogi etifoksyny, ich pochodne i ich zastosowania |
-
2016
- 2016-03-18 PL PL16769437.1T patent/PL3347006T3/pl unknown
- 2016-03-18 MX MX2017011978A patent/MX383647B/es unknown
- 2016-03-18 CN CN201680028306.5A patent/CN107530323B/zh active Active
- 2016-03-18 HR HRP20221240TT patent/HRP20221240T1/hr unknown
- 2016-03-18 SI SI201631611T patent/SI3347006T1/sl unknown
- 2016-03-18 US US15/557,748 patent/US10080755B2/en active Active
- 2016-03-18 RS RS20220948A patent/RS63654B1/sr unknown
- 2016-03-18 WO PCT/US2016/023231 patent/WO2016154039A1/en not_active Ceased
- 2016-03-18 ES ES16769437T patent/ES2928396T3/es active Active
- 2016-03-18 DK DK16769437.1T patent/DK3347006T3/da active
- 2016-03-18 JP JP2018500276A patent/JP6762507B2/ja active Active
- 2016-03-18 AU AU2016235495A patent/AU2016235495B2/en active Active
- 2016-03-18 LT LTEPPCT/US2016/023231T patent/LT3347006T/lt unknown
- 2016-03-18 EP EP16769437.1A patent/EP3347006B1/en active Active
- 2016-03-18 CA CA2979853A patent/CA2979853C/en active Active
- 2016-03-18 KR KR1020177028263A patent/KR102290766B1/ko active Active
- 2016-03-18 BR BR112017020081-3A patent/BR112017020081B1/pt active IP Right Grant
- 2016-03-18 PT PT167694371T patent/PT3347006T/pt unknown
- 2016-03-18 HU HUE16769437A patent/HUE060240T2/hu unknown
- 2016-03-18 SM SM20220407T patent/SMT202200407T1/it unknown
- 2016-03-18 IL IL270627A patent/IL270627B2/en unknown
-
2017
- 2017-09-18 IL IL254567A patent/IL254567B/en active IP Right Grant
-
2018
- 2018-09-21 US US16/138,509 patent/US10736901B2/en active Active
-
2020
- 2020-03-09 AU AU2020201728A patent/AU2020201728B2/en active Active
- 2020-08-07 US US16/988,586 patent/US11672805B2/en active Active
- 2020-08-20 JP JP2020139537A patent/JP2021001174A/ja active Pending
-
2022
- 2022-11-02 JP JP2022176234A patent/JP7376668B2/ja active Active
-
2023
- 2023-05-01 US US18/141,999 patent/US12433896B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221240T1 (hr) | Deuterirani analozi etifoksina, njihovi derivati i njihove uporabe | |
| Slattery et al. | Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review | |
| Hosseini et al. | The importance of long non-coding RNAs in neuropsychiatric disorders | |
| Pawluski et al. | Serotonin and motherhood: From molecules to mood | |
| JP2018508592A5 (enExample) | ||
| Simon et al. | Dysfunction of sensory oscillations in autism spectrum disorder | |
| ECSP19048477A (es) | Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
| Deng et al. | Genetics and molecular biology of brain calcification | |
| CO2018009604A2 (es) | Compuesto heterocíclico | |
| Ferrer et al. | Neurochemistry and the non-motor aspects of PD | |
| Bitanihirwe et al. | Perineuronal nets and schizophrenia: the importance of neuronal coatings | |
| HRP20160185T1 (hr) | Spojevi iminotiadiazin dioksida kao inhibitori bace, smjese i njihova uporaba | |
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| HRP20151273T1 (hr) | Heterocikliäśki spojevi fenoksilmetila | |
| PH12016502231B1 (en) | Indolin-2-one or pyrrolo-pyridin-2-one derivatives | |
| EA201790626A1 (ru) | Макроциклические ингибиторы lrrk2-киназы | |
| BR112019004243A2 (pt) | composto, composição farmacêutica, método para inibição de quinase do zíper de leucina dupla, método para tratamento de uma doença mediada por quinase do zíper de leucina dupla e método para obter um efeito em um paciente | |
| CO2018005718A2 (es) | Derivados de indolin-2-ona | |
| de Sousa et al. | Hominins and the emergence of the modern human brain | |
| HRP20220029T1 (hr) | Supstituirani derivati ksantina | |
| MX2016010409A (es) | Combinacion de baclofeno, acamprosato y trigliceridos de cadena media para el tratamiento de trastornos neurologicos. | |
| Mendez | Degenerative dementias: Alterations of emotions and mood disorders | |
| CO6331428A2 (es) | Compuestos que comprenden un grupo ciclobutoxi | |
| BR112014017463A8 (pt) | processo de produção de acrilato de 2-octila por transesterificação | |
| Augustenborg | The endogenous feedback network: A new approach to the comprehensive study of consciousness |